PRDM9 and cancer: Given that various histone methyltransferases are targeted for therapeutic treatment in cancers, our discovery of initial cell loss followed by over-proliferation in response to knockdown of a key histone methyltransferase raises concerns about the potential use of these enzyme inhibitors in cancer therapy (Morera et al., 2016).